Tesamorelin, Ipamorelin

Tesamorelin, Ipamorelin – Benefits & Side Effects

Tesamorelin, Ipamorelin – Protocol

Tesamorelin, Ipamorelin – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Tesamorelin, Ipamorelin – Identification

Tesamorelin:

Common Names and Synonyms:

• Tesamorelin (USAN designation)

• Egrifta SV (trade name)

• Egrifta (original trade name)

• TH-9507 (research designation)

• Growth hormone-releasing factor analogue

• GHRH analog

• GRF 1-44

Chemical Identification Parameters:

• CAS Number: 218949-48-5

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

• Molecular Weight: 5135.86–5136 g/mol (free base); approximately 5196 Da reported by some suppliers

• FDA UNII: Not specified in accessible databases

• DrugBank ID: DB08869

Structural Classification:

• Peptide Type: Non-glycosylated synthetic polypeptide

• Length: 44 amino acids (tetracosapeptide)

• Structure Type: Linear peptide with N-terminal modification

• Biosynthesis: Synthetic (laboratory-synthesized)

• N-terminal Modification: trans-3-Hexenoic acid attached to N-terminus

• Functional Class: Growth hormone-releasing hormone analogue, growth hormone secretagogue, metabolic modulator

Amino Acid Sequence:

• Sequence: Identical to the 44-amino acid sequence of endogenous human GHRH with trans-3-hexenoic acid modification at the N-terminus

• IUPAC Notation: Modified GHRH(1-44) with hexenoic acid conjugation

• Structural Purpose: The trans-3-hexenoic acid modification confers enhanced resistance to dipeptidyl peptidase IV (DPP-IV) degradation compared to native GHRH, extending peptide half-life and biological activity

Ipamorelin:

Common Names and Synonyms:

• Ipamorelin

• NNC-26-0161 (development designation)

• NNC-260161 (alternative notation)

• Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (amino acid sequence)

• Growth hormone secretagogue (GHS)

• Ghrelin mimetic

• Growth hormone releasing peptide

Chemical Identification Parameters:

• CAS Number: 170851-70-4 (free base)

• Molecular Formula: C₃₈H₄₉N₉O₅

• Molecular Weight: 711.85–711.9 g/mol

• FDA UNII: Not specified in accessible databases

• Exact Molecular Weight: 711.3857 (measured by mass spectrometry)

• Elemental Analysis: C 64.12%, H 6.94%, N 17.71%, O 11.24%

Structural Classification:

• Peptide Type: Non-glycosylated synthetic polypeptide

• Length: 5 amino acids (pentapeptide)

• Structure Type: Linear peptide with D-amino acid modifications

• Biosynthesis: Synthetic (laboratory-synthesized)

• D-Amino Acid Content: Contains D-2-naphthylalanine and D-phenylalanine residues conferring increased stability and receptor selectivity

• Functional Class: Ghrelin receptor agonist, growth hormone secretagogue, metabolic modulator, prokinetic agent

Amino Acid Sequence:

• IUPAC Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Three-Letter Designation: α-Methylalanine-Histidine-2-Naphthylalanine-Phenylalanine-Lysine (amidated C-terminus)

• One-Letter Designation: X-H-X-F-K-NH₂ (where X represents non-standard amino acids)

• Structural Features: The α-methyl alanine (Aib) at the N-terminus provides conformational constraint; D-2-naphthylalanine provides hydrophobic anchoring at the receptor binding site; C-terminal amidation (NH₂) rather than carboxyl (-COOH) increases biological activity

• Molecular Uniqueness: Derived structurally from GHRP-1 but lacking the central dipeptide Ala-Trp, conferring enhanced selectivity for GH release without additional pituitary hormone stimulation

Physical Properties - Tesamorelin:

• Appearance: White to off-white lyophilized (freeze-dried) powder

• Half-life: 26–38 minutes (subcutaneous administration in humans)

• Stability: Enhanced resistance to dipeptidyl aminopeptidase degradation; superior to native GHRH

• Storage: 2–8°C refrigeration recommended; long-term storage at ≤-18°C

• Solubility: Slightly soluble in water; soluble in aqueous buffer systems

Physical Properties - Ipamorelin:

• Appearance: White to off-white lyophilized (freeze-dried) powder

• Half-life: Approximately 2 hours (plasma elimination)

• Stability: Stable in aqueous solution when refrigerated (2–8°C); susceptible to degradation at room temperature; stable at room temperature for approximately 3 weeks when lyophilized

• Storage: Long-term storage at ≤-18°C; lyophilized form stable at room temperature for ~3 weeks; reconstituted samples should be stored 4°C for 2–7 days or frozen below -18°C for extended periods

• Solubility: Recommended reconstitution in sterile 18MΩ-cm H₂O at ≥100 µg/mL; soluble in aqueous solutions

• Freeze-Thaw Sensitivity: Freeze-thaw cycles should be prevented; carrier proteins (0.1% HSA or BSA) recommended for long-term storage of reconstituted solutions

Salt Forms in Commercial Use:

• Tesamorelin: Acetate salt (most common); trifluoroacetate salt (TFA) alternative

• Ipamorelin: Free base; acetate salt; HCl salt

• Typical Purity: ≥95–97% HPLC purity for both peptides

Database References:

• Tesamorelin PubChem CID: 16137828

• Tesamorelin ChemicalBook CBNumber: Not separately assigned

• Ipamorelin PubChem CID: 9831659

• Ipamorelin ChemicalBook Entry: Available in chemical compound databases

• NCBI Entrez Gene: Ipamorelin available in sequence databases; Tesamorelin may be cross-referenced with GHRH entries

Blend Composition:
The Tesamorelin and Ipamorelin blend is typically supplied in fixed-ratio combinations, commonly encountered formulations include:

• 2X Blend: 5 mg Tesamorelin + 5 mg Ipamorelin (equal mass ratios)

• Other proprietary blends: Varying ratios may be supplied by different manufacturers; some commercial products include additional GHRH analogues (such as CJC-1295 Mod GRF 1-29) in three-peptide combinations

• Molar Ratio Considerations: Despite equal mass ratios, the molar ratio differs substantially due to the significant molecular weight difference (Tesamorelin ~5136 Da vs. Ipamorelin ~712 Da), meaning equal mass ratios provide approximately 7.2 moles of Ipamorelin per 1 mole of Tesamorelin

Tesamorelin, Ipamorelin – Research

Tesamorelin and Ipamorelin form a complementary pair: tesamorelin releases GH from your pituitary over hours via GHRH pathways, while Ipamorelin fires off GH pulses via a different receptor (GHRP), creating both sustained and rhythmic elevation. This mimics healthy young GH secretion—a baseline hum plus periodic spikes. Combined benefits include faster muscle growth, aggressive fat loss (especially visceral/belly fat), better recovery post-workout, improved sleep, and skin collagen boost. Clinical research (mostly in HIV patients with lipodystrophy and healthy aging populations) shows measurable improvements in body composition, metabolic markers, and fibrosis prevention. Below are credible, peer-reviewed findings.

Study: The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Benefits: Muscle density improves 1.5-4.9 Hounsfield units (less intramuscular fat), lean muscle area grows in all trunk muscles (0.6-1.1 cm²), reduced sarcopenia risk, better strength
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/
Summary: Researchers from Harvard, Colorado, and Johns Hopkins analyzed muscle scans (CT) from 193 HIV patients who responded to tesamorelin vs. 148 on placebo. They looked at four trunk muscle groups: belly (rectus and oblique), hip (psoas), and lower back (paraspinal). Over 26 weeks, tesamorelin boosted muscle density (less fat inside muscle tissue) across all four groups—biggest gain in the rectus (4.9 HU, p<0.005). Lean muscle area (pure muscle without fat) also rose significantly in all four groups (range 0.64-1.08 cm², p<0.005). The lean gains were about double the total muscle area gains, showing tesamorelin specifically forces out intramuscular lipid and builds clean tissue. Total lean body mass gained +1.9 kg on tesamorelin vs. no change on placebo. These changes occurred alongside VAT (belly fat) loss, but multivariate analysis showed muscle improvements held up even after adjusting for fat loss—meaning tesamorelin talks directly to muscle tissue, not just indirectly through fat reduction. Clinically, studies show that 2-5 HU muscle density improvements correlate with better balance, fewer falls, and stronger grip in elderly—real-world function gains. HIV patients on long-term antiretrovirals often develop muscle wasting (sarcopenia); this study hints tesamorelin + exercise could reverse that.

Study: Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial
Benefits: Liver fat reduced 37% (relative), normalize liver-to-water ratio, prevent fibrosis progression, reduce inflammation (CRP drops 4.7 mg/L)
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/
Summary: 61 HIV-infected adults with fatty livers (hepatic fat fraction ≥5% by MRI) were randomized to tesamorelin or placebo for 12 months. Baseline liver fat was 13.8% on average (range 5-45%). Tesamorelin dropped liver fat by 4.1% absolute (31% of the placebo group saw no change), a relative 37% reduction. Notably, 35% of tesamorelin subjects normalized liver fat to <5% (clinical remission) vs. only 4% on placebo. VAT shrank 35 cm² on tesamorelin vs. no change placebo. Lean body mass rose +1.9 kg (tesamorelin) vs. no change (placebo)—muscle sparing during fat loss. Fibrosis progression (liver scarring) was prevented in 10.5% of tesamorelin patients vs. progressed in 37.5% of placebo—a huge protective effect. C-reactive protein (inflammation marker) fell 4.7 mg/L on tesamorelin but rose on placebo. Glucose and insulin sensitivity did NOT worsen (safety win). Side effects were minor (injection site reactions). Context: Fatty liver disease affects 30-40% of HIV patients despite viral suppression and modern antiretrovirals—a hidden epidemic. Traditional drugs don't work well. Tesamorelin targets the root: visceral fat and hepatic fat accumulation via GH stimulation. The 37% relative fat reduction rivals lifestyle interventions, but took just a daily shot. This is one of the few trials actually reversing liver pathology in HIV lipodystrophy.

Study: Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity
Benefits: Adipocyte quality improves (denser, smaller, healthier cells), better metabolic function, reduced inflammation per adipocyte, preserved subcutaneous fat
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8243807/
Summary: 341 HIV patients (193 tesamorelin responders, 148 placebo) underwent CT scans to measure not just fat amount but fat density (Hounsfield units—higher HU = better quality). Over 26 weeks, tesamorelin responders experienced VAT density increase +6.2 HU and SAT density increase +4.0 HU, while placebo saw no change. Critically, even after statistically controlling for fat area reduction, VAT and SAT density gains persisted—meaning tesamorelin improved fat quality independent of fat quantity. Why this matters: fatter adipocytes (lower density on CT) are metabolically dysfunctional, hypoxic, inflamed, and leak inflammatory cytokines. Smaller, denser adipocytes secrete more adiponectin (a "good" hormone) and less TNF-α (inflammation). Change in adiponectin correlated with change in fat density—confirming functional improvement. VAT density correlated with markers of liver inflammation and metabolic dysfunction at baseline; post-tesamorelin, better density correlated with lower CRP and better insulin sensitivity markers. Tesamorelin also maintained subcutaneous fat while shrinking visceral fat—another major win, since subcutaneous fat is metabolically protective and isn't the dangerous kind. Translation: Your deep belly fat doesn't just shrink in size; the remaining cells become healthier, smaller, and less inflammatory. It's not just weight loss; it's metabolic remodeling.

Tesamorelin, Ipamorelin – Research Links